---
schema_version: "secwatch.filing_event.v1"
accession: "0001100682-26-000036"
form_type: "8-K"
ticker: "CRL"
cik: "0001100682"
company_name: "CHARLES RIVER LABORATORIES INTERNATIONAL, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:24:00.266336+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Charles River Q1 GAAP EPS $(0.30), non-GAAP $2.06; reaffirms FY2026 guidance

## Summary
- Q1 revenue $995.8M (+1.2% reported, -1.5% organic); GAAP loss $(0.30) vs $0.50 prior year.
- Non-GAAP EPS $2.06, down 12% YoY; non-GAAP operating margin 16.3% vs 19.1%.
- Completed divestiture of CDMO and Cell Solutions to GI Partners on May 6, 2026; European sites expected in May.
- Repurchased $200M of stock in Q1; $800M remaining under $1B authorization.
- Reaffirmed FY2026 organic revenue (-1.5% to -0.5%) and non-GAAP EPS $10.80-$11.30; lowered reported revenue outlook ~50bps due to FX.

## SEC filing metadata
- accession: 0001100682-26-000036
- form_type: 8-K
- ticker: CRL
- cik: 0001100682
- company_name: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100682/000110068226000036/0001100682-26-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100682/000110068226000036/crl-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001100682-26-000036
- JSON: https://secwatch.observer/filing/0001100682-26-000036.json
- Plain text: https://secwatch.observer/filing/0001100682-26-000036.txt

## Source-grounded claims
- claim_id: 658951b4e7669dfb0ab5c0a73f6af4b37f2ce546
  claim: CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported first quarter ended March 28, 2026 results: revenue $995.8 million, net income $(14.8) million, EPS $(0.30). Guidance reaffirmed.
  evidence_excerpt: Securities and Exchange Commission. --- EX-99.1 (EX-99.1) --- NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES FIRST-QUARTER 2026 RESULTS – Reports First-Quarter Revenue of $995.8 Million, GAAP Loss per Share of $(0.30), and Non-GAAP Earnings per Share of $2.06 – – Reaffirms 2026 Guidance for Organic Revenue and Non-GAAP Earnings per Share – – Repurchased $200
  evidence_url: https://www.sec.gov/Archives/edgar/data/1100682/000110068226000036/0001100682-26-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.